Efficacy and safety of tadalafil for the treatment of erectile dysfunction in diabetic patients

Abstract EN

Objective : We evaluated the efficacy and safety of tadalafil, a potent, selective phosphodiesterase 5 inhibitor, for the treatment of erectile dysfunction in diabetic patients.

Patients and Methods : Between September 2008 to July 2010, 124 men their mean age was 49.8 years with a clinical diagnosis of type 1 or type 2 diabetes (mean duration 11.7 years), a minimum 3-month history of mild-to-severe ED, (60.5 %) of them had moderate ED of ≥ 1 year's duration were randomly allocated to one of two groups : the first group receive placebo (n = 61), the second group receive tadalafil 20 mg as needed (n = 63) for 12 weeks the dose taken as needed without food restrictions.

Changes from baseline of erectile dysfunction to the ability to complete successful sexual intercourse and the side effect of the drug was noticed and fallowed.

Results : A total of 109 (88 %) of 124 patients completed the study.

Patients receiving 20 mg tadalafil experienced a significant mean improvement, 75 % of them were successfully completed intercourse attempts compared with 28 % in the control group (p < 0.001).

Compared with placebo, tadalafil significantly improve the outcomes.

Tadalafil was consistently efficacious across disease severities and etiologies, as well as in patients of all ages.

Tadalafil was well tolerated, and the most common adverse events were headache (11.2 %), dyspepsia (6.0 %), nasopharyngitis (4.7 %), and flushing (2.8 %).

Conclusions : Tadalafil therapy significantly enhanced erectile function and was well tolerated by men with diabetes and ED.